We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin‐18 isoform 2 splicing variants in gastric cancer and other solid tumours.
- Authors
Katoh, Masuko; Nakayama, Izuma; Wainberg, Zev A; Shitara, Kohei; Katoh, Masaru
- Abstract
This article explores the role of splicing variants in cellular processes and their potential as targets for cancer treatments. Specifically, it focuses on two splicing variants, FGFR2b and CLDN18.2, which are overexpressed in gastric and other solid tumors. The article discusses two biologic drugs, bemarituzumab and zolbetuximab, that target these splicing variants in gastric and gastroesophageal junction adenocarcinoma patients. Bemarituzumab has shown promising results in phase I and II studies, while zolbetuximab has achieved positive outcomes in phase III studies. Ongoing clinical trials are further investigating the use of these drugs and their potential in other types of cancer.
- Subjects
FIBROBLAST growth factor 2; FIBROBLAST growth factor receptors; ECULIZUMAB; STOMACH cancer; MONOCLONAL antibodies; PANCREATIC intraepithelial neoplasia; ANTIBODY-dependent cell cytotoxicity
- Publication
Clinical & Translational Medicine, 2024, Vol 14, Issue 6, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.1736